Is it the creative or the anabolic androgenic steroids? Need for assessing the steroids role in testicular cancer

Patrick Cazorla-Saravia*1 and Renée Pereyra-Elias1

1MD Escuela de medicina, Universidad Peruana de Ciencias Aplicadas, Calle El Paraíso 170, La Molina, Lima 12, Peru

Sir,

We have read with considerable interest the case-control study by Li et al. (2015), in which muscle building supplement (MBS) use was found as an associated factor with testicular germ cell cancer. It is important to remark that the association remained statistically significant even after controlling for important potential confounders. However, we consider that there is one non-assessed variable that might be relevant in the multi-causal model for testicular cancer.

Previous research shows that the frequency of anabolic androgenic steroid (AAS) use within practitioners of recreational physical activity can be as high as 30 (Abrahin et al., 2014) to 50% (Dodge et al., 2011). Therefore, there is high probability of concomitant AAS and MBS use. In addition, AASs have been associated with the development of some types of cancer. Nandrolone and stanozolol, two of the most used AASs, have proven to enhance Leydig cell proliferation, increasing the risk of tumour development in rats (Chimenti et al., 2012). There is also suggestive evidence that involves AAS in Leydig cell tumour growth in humans (Belli et al., 2013). This scenario, AAS could be playing an undetected role in malignancy development instead of or in conjunction with MBS.

Moreover, two recently published articles detected the presence of AAS in products marketed as dietary supplements (Abbate et al., 2014; Odoardi et al., 2012). Thus, the MBS consumed by Li’s study participants could have been contaminated with AAS. This highly probable mix of substances does not allow us to convincingly blame one specific compound.

In summary, Li’s results provide valuable information suggestive of MBS use as a potential risk factor for testicular cancer. However, future research considering the potential AAS effect should be carried out in order to clarify the real influence of this substance.

REFERENCES

Abbate V, Kicman AT, Evans-Brown M, McVeigh J, Cowan DA, Wilson C, Coles SJ, Walker CJ (2014) Anabolic steroids detected in bodybuilding dietary supplements – a significant risk to public health. Drug Test Anal 7: 609–618.

Abrahim OS, Sousa EC, Santos AM (2014) Prevalence of the use of anabolic-androgenic steroids in Brazil: a systematic review. Subst Use Misuse 49(9): 1156–1162.

Belli S, Guidi A, Simoni M, Carani C, Granata AR (2013) Leydig cell tumor in an anabolic steroid abuser. J Endocrinol Invest 36(10): 913.

Chimenti A, Sirtanni R, Zolla, De Luca A, Lanzino M, Catalano S, Ando S, Pezzi V (2012) Nandrolone and stanozolol induce Leydig cell tumor proliferation through an estrogen-dependent mechanism involving IGF-I system. J Cell Physiol 227: 2079–2088.

Dodge T, Hoagland MF (2011) The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend 114: 100–109.

Li N, Hausser R, Holford T, Zhu Y, Zhang Y, Bassij RA, Honig S, Chen C, Boyle P, Dai M, Schwartz SM, Morey P, Sayward H, Hu Z, Shen H, Gomery P, Zheng T (2015) Muscle-building supplement use and increased risk of testicular germ cell cancer in men from Connecticut and Massachusetts. Br J Cancer 112: 1247–1250.

Odoardi S, Castrignano E, Martello S, Chiarotti M, Strano-Rossi S (2015) Determination of anabolic agents in dietary supplements by liquid chromatography-high-resolution mass spectrometry. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 32(5): 653–647.
never an issue for skull base tumours. We wonder whether laryngectomies were done for late unexpected toxicity?

It should be stressed that choosing to employ intra-arterial monochemo-therapy and not systemic polychemotherapy could have reduced the positive effect of systemic therapy in preventing disease metastatisation. This fact should be discussed also in light of the fact that 50% of the recurrences in the experimental arm was at a distant site.

The paper presents long-term data about outcome, but no data about late toxicities are reported. Previous studies showed late effects (brain necrosis, osteonecrosis, hearing or visual problems) as possible limiting toxicities of intra-arterial chemotherapy (Homma et al, 2009, 2013).

Keeping all these observations in mind, it is hard to agree with the authors’ conclusions, suggesting that this new method of chemotherapy could be safe and with promising applications for advanced paranasal sinus cancer.

REFERENCES
Dulguerov P, Allal AS (2006) Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg 14(2): 67–72.
Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kowalski LP, Levine PA,
Medina Dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP (2005) Craniofacial resection for malignant paranasal sinus tumors: report of an International Collaborative Study. Head Neck 27(7): 575–584.
Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, Onimaru R, Nishioka T, Shirato H, Fukuda S (2009) Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer 115(20): 4705–4714.
Homma A, Sakashita T, Yoshida D, Onimaru R, Tsuchiya K, Suzuki F, Yasuda K, Hatakeyama H, Furusawa J, Mizumachi T, Kano S, Inamura N, Taki S, Shirato H, Fukuda S (2013) Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer. Br J Cancer 109(12): 2980–2986.
Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, Pfister DG, Zelefsky MJ, Shah JP, Kraus DH, Lee NY (2008) Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys 72(3): 763–769.
Llorente JL, López F, Suárez C, Hermsen MA (2014) Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 11: 460–472.
Yokoyama J, Ohba S, Fujimaki M, Anzai T, Koijima M, Ikeda K, Suzuki M, Yoshimoto H, Inoue K (2014) Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base. Br J Cancer 111(12): 2229–2234.